Nasdaq
$0.2370▼ 1.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.9MShares out 12.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 3d agoAfter-hours26.10.22 05:12DEFA14AOther#●●●
20/20 Biolabs, Inc.
20/20 Biolabs, Inc. has filed additional definitive proxy soliciting materials. This filing serves as procedural documentation for shareholder voting and the processing of company proposals.…more
$0.2370-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:10DEF 14AOther
20/20 Biolabs, Inc.
20/20 Biolabs will hold a Special Meeting of Stockholders on December 9, 2026, to authorize the board of directors to implement one or more reverse stock splits of its common stock at a ratio between 1-for-2 and 1-for-250. This authorization may be exercised at the board's discretion at any time prior to December 31, 2028.…more
$0.2370-1.21%vs prev closeView filingShare - 10.6After-hours26.10.07 05:33PRE 14AOther
20/20 Biolabs, Inc.
20/20 Biolabs, Inc. has filed a preliminary proxy statement (PRE 14A) regarding matters to be presented at an upcoming shareholder meeting. This filing initiates the formal voting process for company governance and key decision-making.…more
$0.2370-1.21%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Pre-market26.10.02 21:31#●●●#●●●
20/20 BioLabs to Participate in Maxim Growth Summit 2026
20/20 BioLabs management will attend the Maxim Growth Summit in New York to conduct one-on-one meetings with institutional investors. This event serves as an investor relations activity and does not involve new financial results or commercial contracts.…more
$0.2370-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 21:31
●●●●●●●● ●●●●● ●●●●●●
20/20 BioLabs will hold an investor webinar on October 7 to discuss the implications of the recent FDA advisory committee vote and its new OneTest franchise model. The session will cover regulatory strategies for multi-cancer early detection and the company's commercial expansion plans.…more
$0.2370-1.21%vs prev close - 8.28After-hours26.08.29 07:26
●●●●●●●● ●●●●● ●●●●●●
20/20 BioLabs will hold an investor webinar to discuss its record-breaking second-quarter revenue and ongoing commercial expansion strategies. Management will provide insights into the growth of its cancer detection platform and future market opportunities.…more
$0.2370-1.21%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report